Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Share, until 11:59 p.m., Eastern time on Thursday 11 August 2022, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022. All other terms and conditions of the tender offer remain unchanged.
Each CVR represents the right to receive one or more payments in cash, of up to $1.00 per CVR, contingent upon the achievement of certain milestones upon the terms and subject to the conditions described in the Offer to Purchase dated 12 July 2022 (together with any amendments or supplements thereto, the ‘Offer to Purchase’) and in the related Letter of Transmittal.
The tender offer was extended to allow additional time for the condition relating to the expiration or termination of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 as amended (the HSR Condition), to be satisfied.
Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has indicated that, as of 5:00 p.m., Eastern time, on 4 August 2022, approximately 42,256,760 Shares had been validly tendered into and not validly withdrawn from the tender offer, representing approximately 25% of the Shares outstanding as of 6 July 2022.Stockholders who have already tendered their Shares into the tender offer do not have to re-tender their Shares or take any other action as a result of the extension of the expiration time of the tender offer.
Completion of the tender offer remains subject to additional conditions described in the Tender Offer Statement on Schedule TO (as may be amended or supplemented) filed by Purchaser, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS and Ipsen S.A., with the United States Securities and Exchange Commission (SEC) on 12 July 2022. Such conditions include there having been validly tendered and not validly withdrawn Shares that, considered together with all other Shares (if any) beneficially owned by Ipsen Pharma SAS and its subsidiaries, represent at least one Share more than 50% of the total number of Shares outstanding immediately prior to the expiration of the Offer (including any extensions).
Requests for documents and questions regarding the tender offer may be directed to Georgeson LLC, the Information Agent for the tender offer, by telephone (toll-free) at (866) 203-9357 or by email at firstname.lastname@example.org.
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com
Additional Information and Where to Find It
This communication does not constitute an offer to buy or solicitation of an offer to sell Shares. This communication is for informational purposes only. The tender offer is not being made to, nor will tenders be accepted from, or on behalf of, holders of Shares in any jurisdictions in which the making of the tender offer or the acceptance thereof would not comply with the laws of that jurisdiction.
The tender offer is being made pursuant to a Tender Offer Statement on Schedule TO (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) filed by Purchaser, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS and Ipsen S.A. with the SEC on July 12, 2022, as amended or supplemented from time to time. In addition, on 12 July 2022, Epizyme filed a Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, the Solicitation/Recommendation Statement) with the SEC related to the tender offer. EPIZYME’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Shares at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement are available free of charge at the SEC’s website at www.sec.gov.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Adrien Dupin de Saint-Cyr
Investor Relations Manager
+33 6 64 26 17 49
Global Head of Franchise CommunicationsOncology
+44 7840 023 741
Senior Manager Global Media Relations
+33 6 69 09 12 96
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MIR4 Celebrates ‘Sweet Flutter of Love’ Event!7.2.2023 15:00:00 CET | Press release
Wemade’s blockbuster MMORPG MIR4 began the ‘Sweet Flutter of Love’ event on February 7th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005567/en/ MIR4 begins the ‘Sweet Flutter of Love’ event from February 7 (Graphic: Wemade) First, the ‘Sweet 14-day Check-in Event’ will take place until March 6th. Users can obtain ‘Epic Divine Dragon’s Enhancement Stone’, ‘Legendary Blue Dragon Statue’ and more rewards depending on the number of days they’ve checked in. And ‘Cupid Biyoho’s Red Bean Jelly Exchange Shop’ will be open until February 20th. Users can visit the NPC ‘[Cupid] Biyoho’ in a big city to exchange the ‘Red Bean Jelly’ obtained from hunting with 4 types of gift boxes that contain various items such as ‘Summon Tickets’, ‘Enhancement Stones’, and more. MIR4 released a new raid, ‘Forgotten Arena’, with this update. In ‘Forgotten Arena’, monsters spawning in many areas as well as the boss monster ‘Warswine King’ must
LR Health & Beauty receives German Design Award 20237.2.2023 14:25:00 CET | Press release
Last Friday, LR Health & Beauty accepted the German Design Award 2023 in the “Bath and Wellness” category for its “Zeitgard Pro Cosmetic Device”, which was launched in September 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005723/en/ Andreas Laabs (CEO LR Health & Beauty), Uta Landt (Vice President Marketing), Thomas Heursen (General Manager Global Partner Relations) and the entire LR Team rejoice. LR Health & Beauty accepted the German Design Award 2023 for its Zeitgard Pro Cosmetic Device. (Photo: Sabrina Zeuge) In December, LR’s Zeitgard Pro Cosmetic Device had already won the German Design Award in the “Excellent Product Design” competition. On 3rd February, the beauty and health products company, based in Ahlen / Westphalia accepted the award at the official award ceremony hosted by the German Design Council. As a cosmetic device for home use, the Zeitgard Pro combines four different application functions
Future Toyota Cars to be Powerd by RoboSense LiDAR for Safer Self-Driving7.2.2023 14:06:00 CET | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, officially announced its partnership with Toyota, the world's best-selling carmaker, on large-scale production with nominated orders for multiple models. With its advanced technology and product advantages in the global LiDAR field, RoboSense has been officially integrated into Toyota's supply chain system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005749/en/ RoboSense has been officially integrated into Toyota's supply chain system Toyota has been No.1 in global sales for three consecutive years since 2020. In 2022, Toyota sold 10.5 million vehicles, winning the "Best-Selling Automaker" crown. Since the start of the 21st century, Toyota has fully carried out localized production and sales in China and established joint ventures with FAW, GAC, BYD and other domestic auto brands. As a model world-famous joint-venture car brand, a number of featured
NETSCOUT Arbor Cloud Expands Global Network and Capabilities to Help Customers Quickly Mitigate DDoS Cyberattacks7.2.2023 14:05:00 CET | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of performance management, cybersecurity, and DDoS protection solutions, today announced that it has extended its leadership position in DDoS protection by expanding its Arbor Cloud attack mitigation scrubbing centers to 15 worldwide with a dedicated capacity of 15 terabits per second (Tbps). In addition, NETSCOUT added a new presence in Dubai, which allows regional enterprises and ISPs to mitigate DDoS attacks more quickly and efficiently by reducing latency. Part of NETSCOUT’s Adaptive DDoS Defense solution, Arbor Cloud delivers a cloud-based, automated, or on-demand managed DDoS attack mitigation service that provides comprehensive protection against modern day, complex multi-vector DDoS attacks. Working in concert with Arbor Edge Defense (AED), an on-premises, “always-on,” stateless solution installed in-line in the customer network, Arbor Cloud provides a high-availability “backstop” to AED’s real-time DDoS mitigation capab
NetApp Advance Offers Organizations Next Level Hybrid Cloud Flexibility and Efficiency7.2.2023 14:00:00 CET | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the availability of NetApp Advance, a new portfolio of storage programs and guarantees to help customers cost-effectively future proof on-premises environments. NetApp Advance evolves the storage lifecycle, allowing organizations the possibility to avoid complex, costly, and time-consuming refresh cycles by enabling ongoing, non-disruptive hardware upgrades – and ensures efficient, secure and sustainable storage with new guarantees offered to meet the needs of organizations today. With simplified storage ownership and management, NetApp Advance can help to eliminate complex, time-consuming, and costly upgrade cycles while staying current with technology innovations. Organizations can choose on-premises or cloud storage options to future-proof environments to scale securely, seamlessly, and non-disruptively as they grow. Advance also brings sustainability and efficiency best practices and capabil
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom